drugset / Trial / NCT00084565

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00084565

Phase 2 Withdrawn Fox Chase Cancer Center
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel, topotecan, and estramustine together works in treating patients with metastatic hormone therapy-refractory prostate cancer.

Timeline

Start
2003-11
Primary completion
2004-11
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule Intravenous
Subject Topotecan Small molecule Intravenous
Subject estramustine Other / unclassified Oral

Indications